Parallel-group comparative study to evaluate the effect of high-dose nicotinamide mononucleotide (NMN) on aging
- Conditions
- D000368Older adults who do not take medicineolder adults
- Registration Number
- JPRN-jRCTs031220373
- Lead Sponsor
- Yamauchi Toshimasa
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Recruiting
- Sex
- All
- Target Recruitment
- 62
1. Non-smoker
2. Aged 65 years old or older at the time of informed consent is taken
3. Male or female
4. Able to attend all scheduled visits
5. Able and willing to give written informed consent
1. Taking health food
2. With severe hearing loss or wearing a hearing aid in daily life
3. Taking more than 1 hour daily exercise for more than 6 months
4. With a pacemaker
5. Taking medicine, including Chinese medicine
6. Having history of treatment for cancer, heart failure and myocardial infarction
7. With atrial fibrillation, arrhythmia, liver failure, renal failure, cerebrovascular disease, rheumatoid arthritis and other chronic diseases except diabetes, dyslipidemia and hypertension
8. Suspected of having viral hepatitis, HIV or syphilis
9. With drug allergy or with food allergy to health food related to this study
10. Participated in other clinical trials within 3 months
11. Judged as ineligible by clinical investigators
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Change from baseline in hearing ability after 24 weeks of treatment
- Secondary Outcome Measures
Name Time Method 1) Change from baseline in the following items related to aging after 24 weeks of treatment.<br>1.Physical function<br>2. Blood tests<br>3. Biomarkers<br>4. DNA methylation age<br>5. Skin condition<br>6. Exercise tolerance assessed by the 6 minute walk test<br>7. Gut and oral microbiota<br>8. Number of mitochondria<br>9. Quality of Life<br>2) Correlation between blood NAD level and these items.